Biotech and life sciences occupiers in Houston typically cluster in Galleria / Uptown, plan ~320 sqft per seat at high-end fit-out ($155–225/sqft), and pay around 35 USD/sqft ($35 USD) on Class A.
Biotech and life sciences occupiers in Houston typically cluster in Galleria / Uptown, plan ~320 sqft per seat at high-end fit-out">fit-out ($155–225/sqft), and pay around 35 USD/sqft ($35 USD) on Class A.
Biotech and life sciences occupiers in Houston typically anchor in Galleria / Uptown. Energy services, professional services, healthcare, financial services.
Class A rent in Houston runs 35 USD/sqft ($35 USD) on a 10-year lease with 18 months free. Prime submarkets sit at or modestly above the city index.
Typical biotech and life sciences fit-out targets high-end specification at $155–225/sqft. Branded reception, full client-facing programming, premium furniture, and specialist AV are standard.
Plan around 320 sqft per seat blended (workstation + circulation + amenity). A 100-headcount biotech office in Houston typically targets 32,000 sqft of leasable area.
Cluster effects are decisive: PhD-grade talent concentrates near academic-medical anchors and translational research institutes. Deepest energy talent pool in the Americas. Strong engineering, healthcare (Texas Medical Center), and aerospace bases. Tech and finance talent depth is limited compared to Dallas / Austin.
Headline corporate tax: 22.5%. Modified-gross structures with operating-expense pass-throughs. 10-15 year terms common for trophy energy tenants. Free rent of 16-24 months and TI of $80-$140/sqft typical. Heavy concession packages.
| city | Houston |
|---|---|
| industry | Biotech and life sciences |
| naics | 541714, 541715, 325412 |
| preferredSubmarket | Galleria / Uptown |
| preferredFitoutSpec | High-end |
| fitoutBand | $155–225/sqft |
| sqftPerSeat | 320 |
| classARentLocal | 35 USD/sqft/yr |
| classARentUsd | $35/sqft/yr |
| vacancyPct | 26.7% |
| typicalLeaseYears | 10 |
| typicalRentFreeMonths | 18 |
| talentIndex | 78 |
| corporateTaxPct | 22.5% |
Reviewed by Miriam Hollander — Lead market analyst. Last updated 2026-04-15. See our methodology and editorial standards.